Literature DB >> 17906066

The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.

Tina C Wan1, Zhi-Dong Ge, Akihito Tampo, Yasushi Mio, Martin W Bienengraeber, W Ross Tracey, Garrett J Gross, Wai-Meng Kwok, John A Auchampach.   

Abstract

We examined the cardioprotective profile of the new A(3) adenosine receptor (AR) agonist CP-532,903 [N(6)-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] in an in vivo mouse model of infarction and an isolated heart model of global ischemia/reperfusion injury. In radioligand binding and cAMP accumulation assays using human embryonic kidney 293 cells expressing recombinant mouse ARs, CP-532,903 was found to bind with high affinity to mouse A(3)ARs (K(i) = 9.0 +/- 2.5 nM) and with high selectivity versus mouse A(1)AR (100-fold) and A(2A)ARs (1000-fold). In in vivo ischemia/reperfusion experiments, pretreating mice with 30 or 100 microg/kg CP-532,903 reduced infarct size from 59.2 +/- 2.1% of the risk region in vehicle-treated mice to 42.5 +/- 2.3 and 39.0 +/- 2.9%, respectively. Likewise, treating isolated mouse hearts with CP-532,903 (10, 30, or 100 nM) concentration dependently improved recovery of contractile function after 20 min of global ischemia and 45 min of reperfusion, including developed pressure and maximal rate of contraction/relaxation. In both models of ischemia/reperfusion injury, CP-532,903 provided no benefit in studies using mice with genetic disruption of the A(3)AR gene, A(3) knockout (KO) mice. In isolated heart studies, protection provided by CP-532,903 and ischemic preconditioning induced by three brief ischemia/reperfusion cycles were lost in Kir6.2 KO mice lacking expression of the pore-forming subunit of the sarcolemmal ATP-sensitive potassium (K(ATP)) channel. Whole-cell patch-clamp recordings provided evidence that the A(3)AR is functionally coupled to the sarcolemmal K(ATP) channel in murine cardiomyocytes. We conclude that CP-532,903 is a highly selective agonist of the mouse A(3)AR that protects against ischemia/reperfusion injury by activating sarcolemmal K(ATP) channels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906066      PMCID: PMC2435594          DOI: 10.1124/jpet.107.127480

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

1.  Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor.

Authors:  Laura M Kreckler; Tina C Wan; Zhi-Dong Ge; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2005-12-09       Impact factor: 4.030

2.  Human A(2A) adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4).

Authors:  Lauren J Murphree; Melissa A Marshall; Jayson M Rieger; Timothy L MacDonald; Joel Linden
Journal:  Mol Pharmacol       Date:  2002-02       Impact factor: 4.436

3.  A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.

Authors:  H Takano; R Bolli; R G Black; E Kodani; X L Tang; Z Yang; S Bhattacharya; J A Auchampach
Journal:  Circ Res       Date:  2001-03-16       Impact factor: 17.367

4.  Isoflurane preconditioning uncouples mitochondria and protects against hypoxia-reoxygenation.

Authors:  Marko Ljubkovic; Yasushi Mio; Jasna Marinovic; Anna Stadnicka; David C Warltier; Zeljko J Bosnjak; Martin Bienengraeber
Journal:  Am J Physiol Cell Physiol       Date:  2007-01-10       Impact factor: 4.249

5.  Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.

Authors:  Zhi-Dong Ge; Jason N Peart; Laura M Kreckler; Tina C Wan; Marlene A Jacobson; Garrett J Gross; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2006-09-19       Impact factor: 4.030

6.  A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury.

Authors:  J E Jordan; V H Thourani; J A Auchampach; J A Robinson; N P Wang; J Vinten-Johansen
Journal:  Am J Physiol       Date:  1999-11

7.  Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice.

Authors:  Masashi Suzuki; Norihito Sasaki; Takashi Miki; Naoya Sakamoto; Yuki Ohmoto-Sekine; Masaji Tamagawa; Susumu Seino; Eduardo Marbán; Haruaki Nakaya
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

8.  Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.

Authors:  W Ross Tracey; William P Magee; Joseph J Oleynek; Roger J Hill; Andrew H Smith; David M Flynn; Delvin R Knight
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-08-14       Impact factor: 4.733

9.  Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.

Authors:  Richard G Black; Yiru Guo; Zhi-Dong Ge; Sidney S Murphree; Sumanth D Prabhu; W Keith Jones; Roberto Bolli; John A Auchampach
Journal:  Circ Res       Date:  2002-07-26       Impact factor: 17.367

10.  3'-Aminoadenosine-5'-uronamides: discovery of the first highly selective agonist at the human adenosine A3 receptor.

Authors:  Michael P DeNinno; Hiroko Masamune; Lois K Chenard; Kenneth J DiRico; Cynthia Eller; John B Etienne; Jeanene E Tickner; Scott P Kennedy; Delvin R Knight; Jimmy Kong; Joseph J Oleynek; W Ross Tracey; Roger J Hill
Journal:  J Med Chem       Date:  2003-01-30       Impact factor: 7.446

View more
  35 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 2.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

3.  Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Dilip K Tosh; Moshe Chinn; Andrei A Ivanov; Athena M Klutz; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

4.  Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.

Authors:  Lili Du; Zhan-Guo Gao; Kasem Nithipatikom; Adriaan P Ijzerman; Jacobus P D van Veldhoven; Kenneth A Jacobson; Garrett J Gross; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2011-10-19       Impact factor: 4.030

Review 5.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

Review 6.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

8.  Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A3 adenosine receptors in cardiomyoyctes.

Authors:  Tina C Wan; Akihito Tampo; Wai-Meng Kwok; John A Auchampach
Journal:  Biochem Pharmacol       Date:  2019-01-30       Impact factor: 5.858

Review 9.  Impact of hypoglycemic agents on myocardial ischemic preconditioning.

Authors:  Rosa Maria Rahmi Garcia; Paulo Cury Rezende; Whady Hueb
Journal:  World J Diabetes       Date:  2014-06-15

10.  Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor.

Authors:  Yoonkyung Kim; Sonia de Castro; Zhan-Guo Gao; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.